Pfizer (NYSE:PFE) Upgraded by StockNews.com to “Strong-Buy” Rating

Pfizer (NYSE:PFE) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Tuesday.

Several other research firms have also recently weighed in on PFE. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Citigroup assumed coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.06 during mid-day trading on Tuesday, hitting $26.18. The company had a trading volume of 52,915,277 shares, compared to its average volume of 37,728,055. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Pfizer has a 1 year low of $25.20 and a 1 year high of $31.54. The company has a market capitalization of $148.36 billion, a price-to-earnings ratio of 35.38, a P/E/G ratio of 0.85 and a beta of 0.67. The stock’s 50-day moving average price is $28.84 and its 200-day moving average price is $28.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the firm earned ($0.17) EPS. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer will post 2.96 earnings per share for the current year.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On Pfizer

Several large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Pfizer in the 1st quarter valued at approximately $315,000. GSA Capital Partners LLP bought a new position in Pfizer during the first quarter valued at $439,000. Koshinski Asset Management Inc. raised its stake in shares of Pfizer by 20.5% in the first quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock valued at $673,000 after acquiring an additional 4,130 shares during the period. Dearborn Partners LLC boosted its holdings in Pfizer by 18.4% during the 1st quarter. Dearborn Partners LLC now owns 32,683 shares of the biopharmaceutical company’s stock valued at $907,000 after acquiring an additional 5,077 shares during the period. Finally, Private Management Group Inc. grew its position in Pfizer by 270.7% in the 1st quarter. Private Management Group Inc. now owns 26,579 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 19,409 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.